We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Amelioration of Hepatic and Visceral Fat Deposition by Pioglitazone Treatment in Normoglycemic Patients with Metabolic Syndrome.
- Authors
Tsuchiya, Masanobu; Enomoto, Kazuhiro; Nakaoka, Kiyoto; Iijima, Hiroko; Nishio, Yoshihiko; Maegawa, Hiroshi; Kashiwagi, Atsunori
- Abstract
Nonalcoholic fatty liver disease (NAFLD) is frequently associated in patients with metabolic syndrome (MS). We recently reported that Pioglitazone (PIO) treatment ameliorated NAFLD in patients with MS. This study was designed to clarify whether amelioration of hyperinsulinemia by PIO treatment might associate with concomitant improvement of hepatic and visceral fat deposition in normoglycemic patients with MS. The 32 patients with NAFLD and normal glucose tolerance were recruited, and randomly assigned to the treatment or 12 wk with PIO (male 30mg, female 15mg daily) or without PIO (Controls). A 75-g OGTT, laboratory measurements and computed tomograpliy (CT) to determine liver CT values (Hounsfield unit, HU), visceral (V) and subcutaneous (S) fat areas were performed at baseline and after the treatment. Liver CT values and spleen CT values were determined as the mean values for 3 different sites, respectively. After the treatment, the Area of under the curve (AUC) of glucose levels during OGTT was not significantly changed between the 2 groups. However, PIO administration increased liver CT values (48.3 ± 11.7, 56.8 ± 6.3 HU, p<0.01), the liver-to-spleen ratio (0.85 ± 0.20, 1.02 ± 0.10, p<0.001), S (184 ± 42, 203 ± 52 cm², p<0.05), but decreased HOMA-R (p<0.001), the AUC of insulin (p<0.001), V (152 ± 47, 135 ± 39 cm², p<0.05) and V/S (0.86 ± 0.33, 0.71 ± 0.28, p<0.001), as compared with those of Controls. In PIO group, simple linear regression analyses revealed that 12-week change in the AUC of insulin was negatively correlated with changes in liver CT (r = -0.531, p<0.05), but HOMA-R was not. Changes in liver CT was negatively correlated with changes in V (r = -0.538, p<0.05). In conclusion, pioglitazone treatment improves both hepatic and visceral fat deposition, which is correlated with improvement of postprandial insulin concentrations in normoglycemic patients with MS.
- Subjects
THERAPEUTICS; FATTY liver; LIVER diseases; METABOLIC syndrome; HEPATIC manifestations of general diseases; FATTY degeneration
- Publication
Diabetes, 2007, Vol 56, pA153
- ISSN
0012-1797
- Publication type
Article